SMC approves three new medicines for NHS Scotland

SMC approves three new medicines for NHS Scotland PharmacoEconomics & Outcomes News 784, p36 - 12 Aug 2017 SMC approves three new medicines for NHS Scotland The Scottish Medicines Consortium (SMC) has approved three new medicines for routine use by NHS Scotland. Firstly, carfilzomib (Kyprolis) was accepted for use in combination with dexamethasone for the treatment of patients with multiple myeloma. Compared with other current treatments, carfilzomib has a more favourable adverse events profile and has been associated with increased overall and progression-free survival. Secondly, venetoclax (Venclyxto) was accepted by the SMC for the treatment of chronic lymphocytic leukaemia. Venetoclax can potentially improve quality of life and significantly reduce symptoms in this patient group, with participants in the consideration process emphasising that they have limited options when initial treatments fail or are unsuitable. Both carfilzomib and venetoclax were considered via SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines for very rare conditions. Lastly, the SMC accepted desmopressin for the treatment of idiopathic nocturnal polyuria. However, a lack of comparable cost effectiveness meant that 5-aminolaevulinic acid hydrochloride gel (Ameluz) was not approved for routine use by NHS Scotland for basal cell carcinomas that are unsuitable for surgical removal. "The company’s evidence on the economic benefits of the medicine compared to other similar treatments was not sufficient for us to accept it for routine use", commented Chairman of the SMC, Dr Alan MacDonald. Scottish Medicines Consortium. August 2017 decisions news release. Internet Document : 7 Aug 2017. Available from: URL: http:// www.scottishmedicines.org.uk/About_SMC/Latest_news/News_Articles/ August_2017_decisions_news_release 803263882 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

SMC approves three new medicines for NHS Scotland

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/smc-approves-three-new-medicines-for-nhs-scotland-vsxExmcuBf
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4247-6
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p36 - 12 Aug 2017 SMC approves three new medicines for NHS Scotland The Scottish Medicines Consortium (SMC) has approved three new medicines for routine use by NHS Scotland. Firstly, carfilzomib (Kyprolis) was accepted for use in combination with dexamethasone for the treatment of patients with multiple myeloma. Compared with other current treatments, carfilzomib has a more favourable adverse events profile and has been associated with increased overall and progression-free survival. Secondly, venetoclax (Venclyxto) was accepted by the SMC for the treatment of chronic lymphocytic leukaemia. Venetoclax can potentially improve quality of life and significantly reduce symptoms in this patient group, with participants in the consideration process emphasising that they have limited options when initial treatments fail or are unsuitable. Both carfilzomib and venetoclax were considered via SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines for very rare conditions. Lastly, the SMC accepted desmopressin for the treatment of idiopathic nocturnal polyuria. However, a lack of comparable cost effectiveness meant that 5-aminolaevulinic acid hydrochloride gel (Ameluz) was not approved for routine use by NHS Scotland for basal cell carcinomas that are unsuitable for surgical removal. "The company’s evidence on the economic benefits of the medicine compared to other similar treatments was not sufficient for us to accept it for routine use", commented Chairman of the SMC, Dr Alan MacDonald. Scottish Medicines Consortium. August 2017 decisions news release. Internet Document : 7 Aug 2017. Available from: URL: http:// www.scottishmedicines.org.uk/About_SMC/Latest_news/News_Articles/ August_2017_decisions_news_release 803263882 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off